Bethesda-based Northwest Biotherapeutics reported a third-quarter loss of $28.8 million, or 2 cents per share. The cancer drug developer posted revenue of $883,000 for the period.
Reporting from 1 identified publisher for this event.
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Page 2 of 22325
Same format. Every time.
Continue reading — sign in or create a free account with
